Surface Oncology, Inc.: Nasdaq/NYSE listing notice — Surface Oncology transfers to Nasdaq Capital Market; gets extended compliance period to Jan 2, 2024

Surface Oncology, Inc.

Stock transferred from Nasdaq Global Market to Capital Market effective July 10, 2023; ticker remains SURF.
Extended compliance period until January 2, 2024 to regain $1.00 minimum bid price.
Company will consider reverse stock split to regain compliance; no assurance of success.
Previously disclosed bid price deficiency on Jan 6, 2023; initial 180-day period expired July 5, 2023.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Surface Oncology, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

July 6, 2023, Nasdaq notified the Company that the Transfer was approved, and that, in connection with the Transfer, the Company was eligible for an additional 180 calendar day period, or until January 2, 2024 (the “Extended Compliance Date”), to regain compliance with Rule 5550(a)(2). Effective at the opening of business on July 10, 2023, the Common Stock will be transferred to the Nasdaq Capital Market. The Common Stock will continue to trade under the symbol “SURF.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listi

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-184004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.